Conversion ratio between botox®, dysport®, and xeomin® in clinical practice

Toxins

Volumn 8, Issue 3, 2016, Pages

  Scaglione, Francesco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Abobotulinum toxin A; Botulinum neurotoxin; Incobotulinum toxin A; Onabotulinum toxin A

Indexed keywords

BOTULINUM TOXIN A; ACETYLCHOLINE RELEASE INHIBITOR; MUSCLE RELAXANT AGENT; NEUROTOXIN;

BLEPHAROSPASM; CERVICAL DYSTONIA; CLINICAL PRACTICE; CONVERSION RATIO; COST UTILITY ANALYSIS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TREATMENT FAILURE; HEMIFACIAL SPASM; IMMUNOGENICITY; NONHUMAN; PHARMACEUTICAL EQUIVALENCE; PHARMACOLOGICAL PARAMETERS; REVIEW; SPASTICITY; ANIMAL; DYSTONIC DISORDERS; HUMAN; MUSCLE SPASTICITY;

ACETYLCHOLINE RELEASE INHIBITORS; ANIMALS; BOTULINUM TOXINS, TYPE A; DYSTONIC DISORDERS; HUMANS; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; NEUROTOXINS;

EID: 84960080463     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins8030065     Document Type: Review

References (69)

1. Aoki, K.R.; Guyer, B. Botulinum toxin type A and other botulinum toxin serotypes: A comparative review of biochemical and pharmacological actions. Eur. J. Neurol. 2001, 8 Suppl 5, 21–29. [CrossRef][PubMed]
2. Dressler, D.; Benecke, R. Pharmacology of therapeutic botulinum toxin preparations. Disabil. Rehabil. 2007, 29, 1761–1768. [CrossRef][PubMed]
3. Sesardic, D.; Leung, T.; Gaines-Das, R. Role for standards in assays of botulinum toxins: International collaborative study of three preparations of botulinum type A toxin. Biologicals 2003, 31, 265–276. [CrossRef][PubMed]
4. McLellan, K.; Das, R.E.; Ekong, T.A.; Sesardic, D. Therapeutic botulinum type A toxin: Factors affecting potency. Toxicon 1996, 34, 975–985. [CrossRef]
5. Chen, J.J.; Dashtipour, K. Abo-, Inco-, Ona-, and Rima-Botulinum toxins in clinical therapy: A primer. Pharmacotherapy 2013, 33, 304–318. [CrossRef][PubMed]
6. Frevert, J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R & D 2015, 15, 1–9.
7. Benecke, R.; Jost, W.H.; Kanovsky, P.; Ruzicka, E.; Comes, G.; Grafe, S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005, 64, 1949–1951. [CrossRef][PubMed]
8. Roggenkamper, P.; Jost, W.H.; Bihari, K.; Comes, G.; Grafe, S.; NT 201 blepharospasm study team. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J. Neural Transm. 2006, 113, 303–312. [PubMed]
9. Jost, W.H.; Kohl, A.; Brinkmann, S.; Comes, G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J. Neural Transm. 2005, 112, 905–913. [CrossRef][PubMed]
10. Park, J.; Lee, M.S.; Harrison, A.R. Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm. Clin. Ophtalmol. 2011, 5, 725–732.
11. Zoons, E.; Dijkgraaf, M.G.W.; Dijk, J.M.; van Schaik, I.N.; Tijssen, M.A. Botulinum toxin as treatment for focal dystonia: A systematic review of the pharmaco-therapeutic and pharmaco-economic value. J. Neurol. 2012, 259, 2519–2526. [CrossRef][PubMed]
12. Dressler, D.; Mander, G.; Fink, K. Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay. J. Neural Transm. 2012, 119, 13–15. [CrossRef][PubMed]
13. Aoki, K.R.; Ranoux, D.; Wissel, J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur. J. Neurol. 2006, 13 Suppl 4, 10–19. [CrossRef][PubMed]
14. Wohlfarth, K.; Goschel, H.; Frevert, J.; Dengler, R.; Bigalke, H. Botulinum A toxins: Units versus units. Arch. Pharmacol. 1997, 355, 335–340. [CrossRef]
15. Marchetti, A.; Magar, R.; Findley, L.; Larsen, J.P.; Pirtosek, Z.; Ruzicka, E.; Jech, R.; Sławek, J.; Ahmed, F. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study. Mov. Disord. 2005, 20, 937–944. [CrossRef][PubMed]
16. Marion, M.H.; Sheehy, M.; Sangla, S.; Soulayrol, S. Dose standardisation of botulinum toxin. J. Neurol. Neurosurgery Psychiatry 1995, 59, 102–103. [CrossRef]
17. Whurr, R.; Brookes, G.; Barnes, C. Comparison of dosage effects between the American and British botulinum toxin A product in the treatment of spasmodic dysphonia. Mov. Disord. 1995, 10. [CrossRef]
18. Kollewe, K.; Mohammadi, B.; Dengler, R.; Dressler, D. Hemifacial spasm and reinnervation synkinesias: Long-term treatment with either Botox or Dysport. J. Neural Transm. 2010, 177, 759–763. [CrossRef][PubMed]
19. Odergren, T.; Hjaltason, H.; Kaakkola, S.; Solders, G.; Hanko, J.; Fehling, C.; Marttila, R.J.; Lundh, H.; Gedin, S.; Westergren, I., et al. A double-blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J. Neurol. Neurosurgery Psychiatry 1998, 64, 6–12. [CrossRef]
20. Shin, J.H.; Jeon, C.; Woo, K.I.; Kim, Y.D. Clinical comparability of Dysport and Botox in essential blepharospasm. J. Korean Ophthalmol. Soc. 2009, 50, 331–335. [CrossRef]
21. Wohlfarth, K.; Schwandt, I.; Wegner, F.; Jürgens, T.; Gelbrich, G.; Wagner, A.; Bogdahn, U.; Schulte-Mattler, W. Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers: A double-blind, randomized, dose-ranging study. J. Neurol. 2008, 255, 1932–1939, Erratum in J. Neurol. 2009, 256, 1201. [CrossRef]
22. Mohammadi, B.; Buhr, N.; Bigalke, H.; Krampfl, K.; Dengler, R.; Kollewe, K. A long-term follow up of botulinum toxin A in cervical dystonia. Neurol. Res. 2009, 31, 463–466. [CrossRef][PubMed]
23. Rystedt, A.; Nyholom, D.; Naver, H. Clinical experience of dose conversion ratios between toxin products in the treatment of cervical dystonia. Clin. Neuropharmacol. 2012, 35, 278–282. [CrossRef][PubMed]
24. Sampaio, C.; Ferreira, J.J.; Simões, F.; Rosas, M.J.; Magalhães, M.; Correia, A.P.; Bastos-Lima, A.; Martins, R.; Castro-Caldas, A. Dysport: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox, assuming a ratio of 4:1. Mov. Disord. 1997, 12, 1013–1018. [CrossRef][PubMed]
25. Nussgens, Z. Comparison of two botulinum toxin preparations in the treatment of essential blepharospasm. Graefe1s Arch. Clin. Exp. Ophthalmol. 1997, 235, 197–199.
26. Tidswell, P.; King, M. Comparison of Two Botulinum Toxin Type-A Preparations in the Treatment of Dystonias; World Congress of Neurology: London, UK, 2001.
27. Ranoux, D.; Gury, C.; Fondarai, J.; Mas, J.L.; Zuber, M. Respective potencies of Botox and Dysport: A double-blind, randomised, crossover study in cervical dystonia. J. Neurol. Neurosurgery Psychiatry 2002, 72, 459–462.
28. Bentivoglio, A.R.; Ialongo, T.; Bove, F.; de Nigris, F.; Fasano, A. Retrospective evaluation of the dose equivalence of Botox and Dysport in the management of blepharospasm and hemifacial spasm: A novel paradigm for a never ending story. Neurol. Sci. 2012, 33, 261–267. [CrossRef][PubMed]
29. Poewe, W. Respective potencies of Botox and Dysport: A double blind, randomised, crossover study incervical dystonia. J. Neurol. Neurosurgery Psychiatry 2002, 72. [CrossRef]
30. Sampaio, C.; Costa, J.; Ferreira, J.J. Clinical comparability of marketed formulations of botulinum toxin. Mov. Disord. 2004, 19 (Suppl 19), S129–S136. [CrossRef][PubMed]
31. Van den Bergh, P.Y.K.; Lison, D.F. Dose standardization of botulinum toxin. Adv. Neurol. 1998, 78, 231–235. [PubMed]
32. Rosales, R.L.; Bigalke, H.; Dressler, D. Pharmacology of botulinum toxin: Differences between type A preparations. Eur. J. Neurol. 2006, 13 (Suppl 1), 2–10. [CrossRef][PubMed]
33. Wohlfarth, K.; Sycha, T.; Ranoux, D.; Naver, H.; Caird, D. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: Time for a reassessment? Curr. Med. Res. Opin. 2009, 25, 1573–1584. [CrossRef][PubMed]
34. Keren-Capelovitch, T.; Jarus, T.; Fattal-Valevski, A. Upper extremity function and occupational performance in children with spastic cerebral palsy following lower extremity botulinum toxin injections. J. Child Neurol. 2010, 25, 694–700. [CrossRef][PubMed]
35. Brockmann, K.; Schweitzer, K.; Beck, G.; Wächter, T. Comparison of different preparations of botulinumtoxinA in the treatment of cervical dystonia. Neurol. Asia 2012, 17, 115–119.
36. Kollewe, K.; Mohammadi, B.; Köhler, S.; Pickenbrock, H.; Dengler, R.; Dressler, D. Blepharospasm: Long-term treatment with either Botox®, Xeomin®or Dysport®. J. Neural Transm. 2015, 122, 427–431. [CrossRef][PubMed]
37. Rystedt, A.; Zetterberg, L.; Burman, J.; Nyholm, D.; Johansson, A. A comparison of Botox 100 U/mL and Dysport 100 U/mL using dose conversion ratio 1:3 and 1:1.7 in the treatment of cervical dystonia: A double-Blind, randomized, crossover trial. Clin. Neuropharmacol. 2015, 38, 170–176. [CrossRef][PubMed]
38. Yun, J.Y.; Kim, J.W.; Kim, H.T.; Chung, S.J.; Kim, J.M.; Cho, J.W.; Lee, J.Y.; Lee, H.N.; You, S.; Oh, E., et al. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: A double-blind, randomized study. Mov. Disord. 2015, 30, 206–213. [CrossRef][PubMed]
39. Hambleton, P.; Pickett, A.M. Potency equivalence of botulinum toxin preparations. J. R. Soc. Med. 1994, 87, 719. [PubMed]
40. Highlights of prescribing information. Available online: http://www.allergan.com/assets/pdf/botox_pi.pdf (accessed on 10 January 2016).
41. Dysport 300 units, Dysport 500 units—Summary of Product. Available online: https://www.medicines.org.uk/emc/medicine/870/SPC/Dysport+300+units,+Dysport+500+units/ (accessed on 16 February 2016).
42. Full prescribing information—Xeomin. Available online: http://www.xeomin.com/consumers/pdf/xeomin -full-prescribing-information.pdf (accessed on 16 February 2016).
43. Wagman, J.; Bateman, J.B. Botulinum type A toxin: Properties of toxic dissociation product. Arch. Biochem. Biophys. 1953, 46, 375–383. [CrossRef]
44. Eisele, K.H.; Fink, K.; Vey, M.; Taylor, H.V. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 2011, 57, 555–565. [CrossRef][PubMed]
45. Carli, L.; Montecucco, C.; Rossetto, O. Assay of diffusion of different botulinum neurotoxin type A formulations injected in the mouse leg. Muscle Nerve 2009, 40, 374–380. [CrossRef][PubMed]
46. Brodsky, M.A.; Swope, D.M.; Grimes, D. Diffusion of botulinum toxins. Tremor Other Hyperkinet. Mov. 2012, 2, 1346. Available online: http://tremorjournal.org/article/view/85 (accessed on 16 February 2016).
47. Roche, N.; Schnitzler, A.; Genet, F.F.; Durand, M.C.; Bensmail, D. Undesirable distant effects following botulinum toxin type A injection. Clin. Neuropharmacol. 2008, 31, 272–280. [CrossRef][PubMed]
48. Pickett, A. Dysport: Pharmacological properties and factors that influence toxin action. Toxicon 2009, 54, 683–689. [CrossRef][PubMed]
49. Kromminga, A.; Schellekens, H. Antibodies against erythropoietin and other protein based therapeutics: An overview. Ann. N.Y. Acad. Sci. USA 2005, 1050, 257–265. [CrossRef][PubMed]
50. Dressler, D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur. Neurol. 2002, 48, 26–29. [CrossRef][PubMed]
51. Bakheit, A.M.; Liptrot, A.; Newton, R.; Pickett, A.M. The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity. Int. J. Rehabil. Res. 2012, 35, 36–39. [CrossRef][PubMed]
52. Benecke, R. Clinical relevance of botulinum toxin immunogenicity. Biodrugs 2012, 26, e1–e9. [CrossRef][PubMed]
53. Kukreja, R.; Chang, T.-W.; Cai, S.; Lindo, P.; Riding, S.; Zhou, Y.; Ravichandran, E.; Singh, B.R. Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. Toxicon 2009, 53, 616–624. [CrossRef][PubMed]
54. Atassi, M.Z. On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin haemagglutinin. Microbiology 2006, 152, 1891–1895. [CrossRef][PubMed]
55. Atassi, M.Z. Basic immunological aspects of botulinum toxin therapy. Mov. Disord. 2004, 19 (Suppl 8), S68–S84. [CrossRef][PubMed]
56. Bigalke, H. Properties of pharmaceutical products of botulinum neurotoxins. In Botulinum Toxin: Therapeutic Clinical Practice and Science; Jankovic, J., Albanese, A., Atassi, M.Z., Dolly, J.O., Hallett, M., Mayer, N.H., Eds.; Saunders Elsevier: Philadelphia, PA, USA, 2009; pp. 389–397.
57. Frevert, J. Content of botulinum neurotoxin in Botox/Vistabel, Dysport/Azzalure, and Xeomin/Bocouture. Drugs R & D 2010, 10, 67–73.
58. Jankovic, J.; Esquenazi, A.; Fehlings, D.; Freitag, F.; Lang, A.; Naumann, M. Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin. Neuropharmacol. 2004, 27, 234–244. [CrossRef][PubMed]
59. Lundström, E.; Smits, A.; Borg, J.; Terént, A. Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: The first year after the event. Stroke 2010, 41, 319–324. [CrossRef][PubMed]
60. Francis, H.P.; Wade, D.T.; Turner-Stokes, L.; Kingswell, R.S.; Dott, C.S.; Coxon, E.A. Does reducing spasticity translate into functional benefit? An exploratory meta-analysis. J. Neurol. Neurosurgery Psychiatry 2004, 75, 1547–1551. [CrossRef][PubMed]
61. Lukban, M.B.; Rosales, R.L.; Dressler, D. Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: A summary of evidence. J. Neural Transm. 2009, 116, 319–331. [CrossRef][PubMed]
62. Ward, A.; Roberts, G.; Warner, J.; Gillard, S. Cost-effectiveness of botulinum toxin type A in the treatment of post-stroke spasticity. J. Rehabil. Med. 2005, 37, 252–257. [CrossRef][PubMed]
63. Shaw, L.; Rodgers, H.; Price, C.; vanWijck, F.; Shackley, P.; Steen, N.; Barnes, M.; Ford, G.; Graham, L.; BoTULS Investigators. BoTULS: A multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technol. Assess. 2010, 14, 1–113. [CrossRef][PubMed]
64. Doan, Q.V.; Gillard, P.; Brashear, A.; Halperin, M.; Hayward, E.; Varon, S.; Lu, Z.J. Cost-effectiveness of onabotulinumtoxin A for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland. Eur. J. Neurol. 2013, 20, 773–780. [CrossRef][PubMed]
65. Roze, S.; Kurth, H.; Hunt, B.; Valentine, W.; Marty, R. Evaluation of the cost per patient per injection of botulinum toxin A in upper limb spasticity: Comparison of two preparations in 19 countries. Med. Devices 2012, 5, 97–101.
66. Abogunrin, S.; Brand, S.; Desai, K.; Dinet, J.; Gabriel, S.; Harrower, T. Abobotulinumtoxin A in the management of cervical dystonia in the United Kingdom: A budget impact analysis. Clin. Econ. Outcomes Res. 2015, 7, 441–449. [CrossRef][PubMed]
67. Kazerooni, R.; Broadhead, C. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia. Am. J. Health Syst. Pharm. 2015, 72, 301–307. [CrossRef][PubMed]
68. Grosset, D.G.; Tyrrell, E.G.; Grosset, K.A. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: A review of 257 cases. J. Rehabil. Med. 2015, 47, 183–186. [CrossRef][PubMed]
69. Tilden, D.; Guarnieri, C.; Jackson, D. Cost-effectiveness of incobotulinumtoxin-A with flexible treatment intervals compared to onabotulinumtoxin-A in the management of blepharospasm and cervical dystonia. Value Health 2015, 18, A759. [CrossRef][PubMed]